+49 761-389 49-0
Genomic scars introduced by homologous recombination DNA repair deficiency (HRD) are response biomarkers for effective PARP inhibitor therapy. HRD measurements have the potential to improve cancer
therapy as evidenced by over 100 clinical trials that include HRD today, however standardizing and democratizing HRD measurements remain a challenge.
Features:
• Derived from tumor and matched-normal cell lines
• ~65% tumor fraction blend
• 10 μm curls, DNA yield >100 ng per curl
• FFPE format (3 products):
* Seraseq® FFPE HRD High-Positive (GIS 72 ±3)+
* Seraseq® FFPE HRD Low-Positive (GIS 54 ± 2)
* Seraseq® FFPE HRD Negative (GIS 31 ± 2)+
Genomic Instability Score (GIS) calculated using Illumina TruSight™ Oncology (TSO) 500 HRD RUO assay which calculates a GIS using an algorithm licensed from Myriad Genetics
